Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30,284,111
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
25,748,679
-
Shares change
-
+2,476,504
-
Total reported value, excl. options
-
$1,023,986,857
-
Value change
-
+$107,389,201
-
Put/Call ratio
-
16%
-
Number of buys
-
62
-
Number of sells
-
45
-
Price
-
$39.76
Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q4 2023
As of 31 Dec 2023 Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) had 136 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 25,748,679 shares of stock of the company.
Largest 10 holders included FMR LLC, BlackRock Inc., ALKEON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, ORBIMED ADVISORS LLC, BRAIDWELL LP, Darwin Global Management, Ltd., STATE STREET CORP, PRICE T ROWE ASSOCIATES INC /MD/, and MORGAN STANLEY.
This table shows 136 institutional shareholders of the security as of 31 Dec 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.